TEVA catalyst calendar

TEVA PHARMACEUTICAL INDUSTRIES LTD

Upcoming catalysts
8
Cash runway
Cash generating
Cash & investments
$3655M
Phase 3 programs
4

TEVA PHARMACEUTICAL INDUSTRIES LTD is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on October 28, 2026, a projected date rather than a confirmed one. There are 8 upcoming events on record.

TEVA PHARMACEUTICAL INDUSTRIES LTD generates cash from operations, so a burn-based runway figure does not apply.

Across 12 concluded trials, 58% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 28, 2026 est. Next quarterly earnings (projected) Earnings —
October 31, 2026 A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations Trial Milestone Phase 3
November 2, 2026 A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma Trial Milestone Phase 3
January 15, 2027 A Trial to Assess TEV-56286 at Different Doses in Healthy Participants Trial Milestone Phase 1
September 15, 2027 A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy Trial Milestone Phase 2
April 26, 2028 A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo Trial Milestone Phase 1
May 3, 2029 An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy Trial Milestone Phase 2
May 26, 2029 An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors Trial Milestone Phase 1

Track TEVA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open TEVA in the tracker

Recent history

DateEventTypePhase
October 2, 2026 A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease Trial Milestone Phase 2
September 16, 2026 8-K filed: Material agreement Corporate —
September 14, 2026 8-K filed: Other event Filing —
September 11, 2026 8-K filed: Reg FD disclosure, Other event Filing —
September 3, 2026 8-K filed: Other event Filing —
July 29, 2026 Quarterly results filed (8-K) Earnings —
April 29, 2026 Quarterly results filed (8-K) Earnings —
January 28, 2026 Quarterly results filed (8-K) Earnings —
January 12, 2026 Quarterly results filed (8-K) Earnings —
January 5, 2026 A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease Trial Milestone Phase 2
December 11, 2025 8-K filed: Material agreement Corporate —
November 5, 2025 Quarterly results filed (8-K) Earnings —
October 24, 2025 Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China Trial Milestone Phase 4
August 15, 2025 A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents Trial Milestone Phase 3
August 14, 2025 An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia Trial Milestone Phase 1
July 30, 2025 Quarterly results filed (8-K) Earnings —
June 12, 2025 Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia Trial Milestone Phase 1
May 28, 2025 8-K filed: Material agreement Corporate —
May 22, 2025 8-K filed: Reg FD disclosure, Other event Filing —
May 22, 2025 A Study to Assess New Formulations of TEV-56286 Trial Milestone Phase 1
May 7, 2025 Quarterly results filed (8-K) Earnings —
January 15, 2025 Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder Trial Milestone Phase 1
July 1, 2024 A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma Trial Milestone Phase 1/Phase 2
June 4, 2024 A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Trial Milestone Phase 1
May 22, 2024 A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma Trial Milestone Phase 1/Phase 2
March 19, 2024 A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia Trial Milestone Phase 3
December 20, 2023 A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Trial Milestone Phase 1/Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.